Journal Articles

2017

Osteoarthritis and Cartilage | September 15

Osteoarthritis and Cartilage | July 13

  • A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

    Osteoarthritis and Cartilage, 25(10), 1598-1606. doi:10.1016/j.joca.2017.07.006


    Y. Yazici, T.E. McAlindon, R. Fleischmann, A. Gibofsky, N.E. Lane, A.J. Kivitz, N. Skrepnik, E. Armas, C.J. Swearingen, A. DiFrancesco, J.R.S. Tambiah, J. Hood, M.C. Hochberg

  • Related Review: Osteoarthritis in 2017: Latest advances in the management of knee OA

Conferences

2019

International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit | January 17 - 18

San Diego, California

  • Efficacy and Safety from a Phase 2b Trial of SM04690: A Novel, Intra-Articular Wnt Pathway Inhibitor for the Treatment of Knee Osteoarthritis

2018

New York Academy of Sciences (NYAS) Symposium on Alzheimer's Disease Therapeutics | December 11

New York, New York

  • Tau Pathology Reduction with SM07883, A Novel, Potent, and Selective Oral DYRK1A Inhibitor - Potential Therapeutic for Alzheimer’s Disease

International Conference on Frontotemporal Dementias | November 11 - 14

Sydney, Australia

  • SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor Reduced Tau Pathology in Preclinical Models

World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD) | November 08 - 10

Bangkok, Thailand

  • SM04690, A Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

  • Joint Space Width Criteria Can Reduce Knee Osteoarthritis Trial Heterogeneity: Phase 2 Post-Hoc Data from Wnt Pathway Inhibitor SM04690

  • Results from a 52-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Wnt Pathway Inhibitor (SM04690) for Knee Osteoarthritis Treatment

  • Radiographic Outcomes Were Concordant with Pain and Function Response: Post-Hoc Analysis from a Phase 2 Study of SM04690, a Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment

Clinical Trials on Alzheimer's Disease (CTAD) | October 24 - 27

Barcelona, Spain

  • SM07883, a novel DYRK1A inhibitor, reduced Tau pathology – discovery and preclinical development of a potential therapeutic for Alzheimer’s disease

American College of Rheumatology (ACR) | October 19 - 24

Chicago, Illinois

  • Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee

  • Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway

  • Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor

  • Assessment of Health-Related Quality of Life in a 52-Week, Phase 2, Randomized, Controlled Trial of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Treatment of Knee Osteoarthritis

Asia Pacific League of Associations for Rheumatology (APLAR) | September 06 - 09

Kaohsiung, Taiwan

  • Results from a 52-week, phase 2a study of an intra-articular, small molecule Wnt pathway inhibitor, SM04690, for knee osteoarthritis

Alzheimer’s Association International Conference (AAIC) | July 22 - 26

Chicago, IL

  • Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor - a Potential Therapeutic for Alzheimer’s Disease

International Workshop on Osteoarthritis Imaging (IWOAI) | July 05 - 07

Menton, France

  • Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of Wnt pathway inhibitor, SM04690, for knee osteoarthritis

European League Against Rheumatism (EULAR) | June 13 - 16

Amsterdam, Netherlands

  • Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52 week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor

  • Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway

  • Potential Nociceptive Pain Relief of Intra-Articular Saline Control in Clinical Trials of Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Trials

  • Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of a Wnt pathway inhibitor, SM04690, for knee osteoarthritis treatment

  • Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Psoriasis

  • SM04690, a WNT Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

  • Results from a 52-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Wnt Pathway Inhibitor (SM04690) for Knee Osteoarthritis Treatment

  • Adjusting for the Intra-Articular Placebo Effect in Knee Osteoarthritis Therapies

The Orthobiologic Institute (TOBI) Annual Symposium | June 07 - 09

Las Vegas, NV

  • Results from a 52-Week, Phase 2a Study of an Intra-Articular, Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis

  • SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

  • Preclinical Evidence for SM04690, a Small Molecule Wnt Pathway Inhibitor, as a Potential Treatment for Degenerative Disc Disease

  • A Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Wnt Pathway Inhibitor

American Thoracic Society (ATS) | May 18 - 23

San Diego, CA

  • SM04646 inhibited Wnt pathway gene expression stimulated in response to Transforming Growth Factor-β and was effective in a chronic model of Bleomycin-induced pulmonary fibrosis

International Investigative Dermatology (IID) | May 16 - 19

Orlando, FL

  • Small Molecule Wnt Pathway (SM04755) Inhibitor as a Potential Topical Treatment for Psoriasis

International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting | May 14 - 18

Banff, Canada

  • A Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Treatment for Degenerative Disc Disease

Osteoarthritis Research Society International (OARSI) World Congress | April 26 - 29

Liverpool, United Kingdom

  • Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway

  • SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical Osteoarthritis Models

  • Radiographic Outcomes Were Concordant with Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) Strict Response: Post-Hoc Analysis from a Phase 2 Study of a Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment

  • Joint Space Width Inclusion Criteria Can Reduce Knee Osteoarthritis Trial Heterogeneity: Post-Hoc Data from a Phase 2 Trial of Wnt Pathway Inhibitor, SM04690

  • Results from a 52-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis

World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases | April 19 - 22

Krakow, Poland

  • Results from a 52 Week, Phase 2a Study of an Intra-Articular, Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis

  • Joint Space Width Criteria Can Reduce Knee OA Trial Heterogeneity: Phase 2 Post-Hoc Data from Wnt Pathway Inhibitor, SM04690

  • SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

  • SM04690, a small molecule Wnt pathway inhibitor, appeared to have no deleterious effects on bone, joint, and tissue health in knee OA models

  • SM04690 caused dose-dependent Wnt pathway modulation within a homeostatic range in a rat model of knee osteoarthritis

International Cartilage Repair Society (ICRS) | April 09 - 12

Macao, China

  • SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

  • Radiographic Outcomes Were Concordant with Pain and Function Response: Post-Hoc Analysis from a Phase 2 Study of SM04690, a Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment

  • Joint Space Width Criteria Can Reduce Knee OA Trial Heterogeneity: P2 Post-Hoc Data from Wnt Pathway Inhibitor, SM04690

  • A 52 Week Randomized, Double-Blind Phase 2 Study of Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Osteoarthritis

Pan American League of Associations for Rheumatology (PANLAR) | April 07 - 10

Buenos Aires, Argentina

  • Results from a 52-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis

  • SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting 2018 | March 15 - 18

Turin, Italy

  • Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor – a Potential Therapeutic for Alzheimer’s Disease

Orthopaedic Research Society (ORS) | March 10 - 13

New Orleans, LA

  • Anti-Inflammatory Properties of SM04690, a Small Molecule Inhibitor of the Wnt Pathway as a Potential Treatment for Knee Osteoarthritis

  • Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway

American Academy of Dermatology (AAD) | February 16 - 20

San Diego, CA

  • Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Psoriasis

2017

Pulmonary Fibrosis Foundation Summit (PFF) | November 09 - 11

Nashville, TN

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04646) Delivered as an Inhaled Aerosol for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

American College of Rheumatology (ACR) | November 03 - 08

San Diego, CA

  • Results from a 52 Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis

  • Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway
    Inhibitor in Knee Osteoarthritis

  • Radiographic Outcomes Were Associated with Pain and Function Responses: Post-Hoc Analysis of Results from a Phase 2 Study of a Small Molecule Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment

Orthopaedic Research Society (ORS) Southern California Regional Symposium | September 25

Los Angeles, CA

  • Interim Results from a 52 week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis

  • Cartilage Regeneration in a Rat Model of Knee OA by SM04690, a Potential Disease Modifying Wnt Pathway Inhibitor

Gordon Research Conference: Wnt Signaling | August 06 - 11

Stowe, VT

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

Spine Intervention Society (SIS) | July 19 - 22

San Francisco, CA

  • Discovery of a Small Molecule Wnt Pathway Inhibitor (SM04690) as a Potential Treatment for Degenerative Disc Disease

International Cartilage Repair Society Heritage Summit | June 29 - Jul 01

Gothenburg, Sweden

  • Cartilage Regeneration in a Rat Model of Knee OA by SM04690, a Potential Disease Modifying Wnt Pathway Inhibitor

European League Against Rheumatism (EULAR) | June 14 - 17

Madrid, Spain

  • Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Week 26 Interim Analysis

  • Clinical Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Injectable, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis: Week 26 Interim Analysis

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Anti-inflammatory Properties of SM04690, a Small Molecule Inhibitor of the Wnt Pathway as a Potential Treatment for Knee Osteoarthritis

International Society for Pharmacoeconomics and Outcomes (ISPOR) | May 20 - 24

Boston, MA

  • Health Care Resource Use of Medicare Beneficiaries With Primary Osteoarthritis (OA) Of The Knee – A Claims Data Analysis

  • A Statistical Analysis Plan to Understand Osteoarthritis Patient Journey by Linking Medicare Claims Across Care Delivery Settings

American Thoracic Society (ATS) | May 19 - 24

Washington D.C.

  • Discovery of a Small Molecule Inhibitor of the Wnt pathway (SM04646) Delivered as an Inhaled Aerosol for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Musculoskeletal Regenerative Medicine and Biology: From Development to Regeneration | May 04 - 06

St. Louis, MO

  • Discovery of a Small Molecule Wnt Pathway Inhibitor (SM04690) as a Potential Treatment for Degenerative Disc Disease

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Discovery of a Small Molecule Wnt Pathway Inhibitor (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

Osteoarthritis Research Society International (OARSI) | April 27 - 30

Las Vegas, NV

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Anti-inflammatory Properties of SM04690, a Small Molecule Inhibitor of the Wnt Pathway as a Potential Treatment for Knee Osteoarthritis

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Treatment for Degenerative Disc Disease

Society for Investigative Dermatology (SID) | April 26 - 29

Portland, OR

  • Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Scleroderma Treatment

  • Small Molecule Wnt Pathway Inhibitor (SM04755) as a Potential Topical Psoriasis Treatment

  • A Small Molecule Modulator of the Wnt Pathway (SM04554) as a Potential Topical Treatment for Androgenetic Alopecia (AGA)

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases | March 23 - 26

Florence, Italy

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Discovery of a Small Molecule Wnt Pathway Inhibitor (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

  • Discovery of a Small Molecule Wnt Pathway Inhibitor (SM04690) as a Potential Treatment for Degenerative Disc Disease

Orthopaedic Research Society (ORS) | March 19 - 22

San Diego, CA

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Treatment for Degenerative Disc Disease

American Academy of Dermatology (AAD) | March 03 - 07

Orlando, FL

  • Safety and Biopsy Outcomes of a Topical Treatment (SM04554) for Male Androgenetic Alopecia (AGA): Results from a Phase 2, Multicenter, Randomized, Double-blind, Vehicle-controlled Trial

Musculoskeletal Development and Regeneration Conference (MDRC) | February 24 - 27

Cancun, Mexico

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

2016

American College of Rheumatology (ACR) | November 11 - 16

Washington D.C.

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Chronic Tendinopathy

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Scleroderma

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Treatment for Degenerative Disc Disease

  • Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee

  • A Small Molecule, SM04690, Has Inhibitory Effects on the Wnt Pathway and Inflammation in Vitro, with Potential Implications for the Treatment of Osteoarthritis

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Psoriasis

  • Analysis of Pain and Function Components in Omeract-Oarsi Strict Responders from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee

International Cartilage Repair Society 2016 World Congress (ICRS) | September 24 - 27

Sorrento, Italy

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

Royal Society of Medicine's 13th Medical Innovations Summit | September 17

London, United Kingdom

  • Samumed's Regenerative Medicine Platform

European League Against Rheumatism (EULAR) | June 08 - 11

London, United Kingdom

  • Safety, Clinical and Imaging Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhbitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Exploratory Analysis of Results from a 24 week, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

Osteoarthritis Research Society International (OARSI) | March 31 - Apr 03

Amsterdam, Netherlands

  • OMERACT-OARSI ‘Strict Responders’ Analysis from Results of a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of a Novel, Intra-Articular, Injectable Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

American Academy of Dermatology (AAD) | March 04 - 08

Washington D.C.

  • Safety and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 1 Trial

  • Safety, Tolerability and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 2 Trial

2015

World Congress for Hair Research (WCHR) | November 18 - 21

Miami, FL

  • Safety and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 1 Trial

American College of Rheumatology (ACR) | November 06 - Oct 11

San Francisco, CA

  • Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

  • Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study

  • Discovery of an Intra-Articular Injection Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Disease Modifying Treatment for Knee Osteoarthritis

Award Winning

Privacy Policy Terms of use Contact Us © Samumed, LLC. All rights reserved